CN101862339A - Use of cryptotanshinone as radiation sensitizing medicament in oncotherapy - Google Patents
Use of cryptotanshinone as radiation sensitizing medicament in oncotherapy Download PDFInfo
- Publication number
- CN101862339A CN101862339A CN200910068497A CN200910068497A CN101862339A CN 101862339 A CN101862339 A CN 101862339A CN 200910068497 A CN200910068497 A CN 200910068497A CN 200910068497 A CN200910068497 A CN 200910068497A CN 101862339 A CN101862339 A CN 101862339A
- Authority
- CN
- China
- Prior art keywords
- cryptotanshinone
- application
- group
- cell
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention discloses use of cryptotanshinone as a radiation sensitizing medicament in oncotherapy. The cryptotanshinone has the effects of improving the sensitivity of tumor cells to X-rays and enhancing the inhibiting effect of the X-rays on tumors. The cryptotanshinone is a monomeric compound extracted from a common Chinese medicament danshen root, and has the advantages of low toxin, simple extraction process and the like; the resources of raw materials are rich, and the raw materials are mixed with common pharmaceutic adjuvant to prepare various formulations. The cryptotanshinone has good application and development prospect and is an ideal novel oncology radiation sensitizing medicament.
Description
Technical field
The invention belongs to herbal pharmacology experimentation technical field, relate to cryptotanshinone application as radio sensitization medicine in oncotherapy.Say so more specifically cryptotanshinone in cervical cancer, hepatocarcinoma, breast carcinoma, lung cancer therapy as the application of radio sensitization medicine.
Background technology
In recent years, along with the continuous development of radiation oncology, it is important that the status of radiotherapy in oncotherapy more shows, and radiotherapy has become one of the most frequently used method of current treatment malignant tumor: have 70% to accept radiotherapy in the Chinese tumor patient approximately.But conventional radiotheraphy is to some tumors, and especially the curative effect of some middle and advanced stage tumors is unsatisfactory.This is because solid tumor is grown in the microenvironment of a uniqueness, simultaneously because propagation is too fast, thereby causes the oxygen and the nutrient supply deficiency of tumor cell inside, produces anoxic cell.These anoxic cells not only limited put, the curative effect of chemotherapy, also become the root of problems such as tumor recurrence, radiation resistance, chemical drug resistance.Radiosensitizer then is a class material that can strengthen anoxic cell sensitivity in the entity tumor, and it can strengthen the kill capability of ray to tumor, and is significant for the radiocurable effect of clinical raising.A key issue we can say tumor radiotherapy is how to improve the radiosensitivity of anoxic cell in the tumor body.
For many years, the various countries scholar is devoted to seek the radiosensitizer of high-efficiency low-toxicity always, and the type of compounds with radiosensitizing effect is more.In the various dissimilar radiosensitizer of having studied, based on the electrophilic compound nitro glyoxaline compound.Experimental results demonstrate that nitro glyoxaline compound has radiosensitizing effect, the sub-affinity of its forceful electric power makes it to seize the electronics that ionization produces from the target molecule of radiation function, has reduced the restorative probability of target molecule, and forms the DNA free radical, causes stable damage.Sensitizer can also be further and the DNA combined with radical that produces, and forms stable adduct, cause cell death, but the influence to normal structure is also bigger simultaneously, mainly shows as neurotoxicity.Representing medicine is misonidazole (MISO), but because its peripheral nerve toxicity has limited using dosage, causes the drug level in the tumor not reach the valid density of enhanced sensitivity and limited sensitizing activity.
Because the microenvironment of tumor is extremely complicated, research through many decades, although synthesized a large amount of dissimilar chemical compounds, do not find generally acknowledged low toxicity efficient emission sensitizer so far in the world as yet, the hypoxic cell radiation sensitizer of seeking high-efficiency low-toxicity is still the target that keeps punching.
Seeking ideal radiosensitizer from Chinese herbal medicine, is a promising direction.Modern medicine study shows that blood-activating stasis-removing kind side's medicine can improve the microcirculation of tumor cell, improves the oxygen supply of tumor, reduces hypoxic tumor cells, and the shoulder district of cell survival curve is narrowed down, and weary preferably oxygen sensitization is arranged.
Radix Salviae Miltiorrhizae is the dry root of Labiatae salvia Radix Salviae Miltiorrhizae (Salvia miltiorrhiza Bge.), nature and flavor: bitter in the mouth, be slightly cold.Gui Jing: the heart, percardium, liver.Effect: blood circulation promoting and blood stasis dispelling, heat clearing away and restlessness relieving, blood vessel dilating.Cure mainly: dysmenorrhea, lochia, angina pectoris, borborygmus stomachache, malignant boil toxic swelling.Modern medicine thinks that Radix Salviae Miltiorrhizae has coronary artery dilator, coronary blood flow increasing, prevents cardiovascular effects such as myocardial ischemia and myocardial infarction.
Cryptotanshinone is a fat-soluble phenanthrenequione constituents in the Radix Salviae Miltiorrhizae, and in vitro tests proves, it has stronger inhibitory or killing effect to source of disease bacterium such as golden Portugal bacterium and Resistant strain thereof, streptococcus, mycobacterias.Up to now, do not see the application of cryptotanshinone as the tumor radio sensitization agent.
Summary of the invention:
One object of the present invention has been to disclose cryptotanshinone application as radio sensitization medicine in the medicine of preparation treatment tumor.
Another object of the present invention has been to disclose cryptotanshinone application as radio sensitization medicine in the medicine of preparation treatment cervical cancer.
The present invention also purpose has been to disclose cryptotanshinone application as radio sensitization medicine in preparation treatment liver-cancer medicine.
The present invention also purpose has been to disclose cryptotanshinone application as radio sensitization medicine in the medicine of preparation treatment breast carcinoma.
The present invention also purpose has been to disclose cryptotanshinone application as radio sensitization medicine in preparation treatment lung cancer drugs.
The present invention further provides the pharmaceutical composition that contains as the cryptotanshinone of radiosensitizer, it comprises cryptotanshinone and one or more pharmaceutically acceptable carriers, excipient or diluent.
Containing the cryptotanshinone pharmaceutical composition as active component of the present invention can be according to the conventional medicine preparation technique, prepares by cryptotanshinone composition and pharmaceutically suitable carrier are made up.Carrier can adopt various forms, and this depends on the route of administration (for example oral, parenteral) of hope.Therefore for oral liquid, suitable carriers and additive comprise water, ethylene glycol, oil, ethanol, flavoring agent, antiseptic, stabilizing agent, coloring agent or the like; For oral solid formulation such as powder, capsule or tablet, suitable carriers and additive comprise: diluent, lubricant, binding agent, disintegrating agents or the like such as lactose, starch, sucrose, polyvinylpyrrolidone.Oral solid formulation also can be used as material coatings or enteric coated so that adjust the main position that absorbs such as acrylic resins.For parenteral admistration, as preparations such as topical, transdermal administration and mucosa deliveries, carrier generally includes macromolecular material such as carbomer, absorption enhancer azone or the like.Injection also can utilize water carrier and suitable additives such as caffolding agent mannitol, glycine, solubilizing agent propylene glycol, antioxidant sodium pyrosulfite or the like preparation.Because be easy to administration, tablet and capsule are represented the oral presented in unit dosage form of most convenient.
The every dosage unit of pharmaceutical composition of the present invention for example sheet, capsule, injection or the like should comprise the essential Radix Salviae Miltiorrhizae extract cryptotanshinone that discharges aforesaid effective dose.For example common tabletting composition such as corn starch, lactose, sucrose, sorbitol, Pulvis Talci, stearic acid, magnesium stearate, dicalcium phosphate or glue and other medicinal diluents.For example mix, comprise the solid prescription design team compound of cryptotanshinone of the present invention with formation with water.Comprise syrup, the water of aqueous solution, suitable flavouring or contain edible oil for liquid form, for example the Emulsion of the flavouring of cottonseed oil, Oleum sesami and elixir and similar pharmaceutical carrier.
For addressing the above problem, the invention provides following technical scheme:
The present invention has confirmed that by experiment in vivo and vitro cryptotanshinone has the radio sensitization effect.External employing clone forms experiment, and cryptotanshinone is observed the radiosensitizing effect of s, and the result shows that cryptotanshinone is 1.4 to s enhanced sensitivity ratio.Experiment in the whole animal body, adopt high, medium and low three dosage that the radiosensitizing effect of lotus EMT6 breast carcinoma, Lewis lung cancer, H22 liver cancer mouse is observed, adopt the tumor growth delay method to observe sensitization, the result shows, cryptotanshinone to H22 liver cancer mouse enhanced sensitivity coefficient up to 1.91; To EMT6 breast carcinoma mice enhanced sensitivity coefficient up to 1.78; To Lewis lung cancer mice enhanced sensitivity coefficient up to 1.58; Compare with matched group, statistical significance is arranged.Conclusion: cryptotanshinone all has radiosensitizing effect preferably to s and lotus breast carcinoma, pulmonary carcinoma and liver cancer mouse.
Description of drawings:
Fig. 1 clicks the cell survival curve of model match for many targets.
The specific embodiment
In order to explain enforcement of the present invention more fully, provide following embodiment.These embodiment explain rather than limit the scope of the invention.The inventor has successively finished cryptotanshinone as the pharmacological evaluation of radiosensitizer at aspects such as treatment cervical cancer, hepatocarcinoma, breast carcinoma, pulmonary carcinoma, is the pharmacological experiment study and the result of cryptotanshinone below.Cryptotanshinone is wherein provided by Chinese medicine and biological products assay institute.
Embodiment 1:
Cryptotanshinone is to the radiosensitizing effect of s
Material and method
1. reagent and medicine:
DMEM (Dulbecco ' s Modified Eagle Medium) available from Gibco company; MTT (tetrazole Thiazolyl blue, tetramethyl azo azoles salt) is available from Shanghai biological engineering company limited; Ox blood serum grinds institute available from China Concord Medical Science University's blood; Cryptotanshinone is provided by Chinese medicine and biological products assay institute, is dissolved in an amount of dimethyl sulfoxine (DMSO), and final concentration is 0.1%, filtration sterilization, and 4 ℃ of refrigerator sealings are kept in Dark Place.
2. instrument and equipment:
CO
2Incubator: U.S. Thermo Electron Corporation; Superclean bench: Suzhou elite equipment company; Inverted phase contrast microscope: Japanese Olympus company; BIO-RAD MODE 1680 type microplate reader; Tissue Culture Plate: Japanese IWAKI.
3. cell strain and cell culture:
Human cervical carcinoma cell strain Hela purchases the cell centre in Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences.The Hela cell inoculation places 37 ℃, 5%CO in DMEM culture fluid (containing 10% new-born calf serum and penicillin, each 100U/ml of streptomycin)
2Cultivate in the incubator of saturated humidity, the Hela cell is a fusiformis, is adherent growth, goes down to posterity with 0.25% trypsinization after hatching 2-3d, selects the exponential phase cell to experimentize.
4.MTT method detects the inhibitory action of cryptotanshinone to the Hela cell proliferation:
The take the logarithm Hela cell of trophophase, make single cell suspension with 0.25% trypsinization after, cell counting is adjusted into 2 * 104/ml with cell concentration, is inoculated in 96 well culture plates, the blank group gives isopyknic PBS; The administration group adds the cryptotanshinone of variable concentrations respectively.The concentration of administration group is followed successively by: 0.5,1,2,4,8,10,16 μ g/ml, each concentration is established 6 multiple holes.After cultivating 24h, 48h, 72h respectively, add the MTI liquid (20 μ l/ hole) of 5mg/ml, continue at 5%CO
2Incubator is hatched 4h, inhales and removes supernatant, adds dimethyl sulfoxide (DMSO) 150 μ l/ holes, miniature oscillator concussion 10min makes complete mixing dissolving crystallized, on microplate reader in its absorbance of wavelength 492nm place survey, each dosage is established parallel repetition 6 holes, and experiment repeats 3 times.Calculate suppression ratio as follows, ask IC50 value and IC20 value after the match.
Cell inhibitory rate (%)=(1 one test group OD meansigma methodss/matched group OD meansigma methods) * 100%.
5. the clone forms experiment:
Behind the drug effect, inhibitory rate of cell growth is in 20% the time, and the toxic action of medicine pair cell can be ignored relatively, so when selecting cryptotanshinone effect 24h, suppress the concentration (IC20) of cell proliferation 20% and test.If dosing irradiation group and simple irradiation group, exposure dose is respectively 0,1,2,3,4,6,8Gy.Cell number according to different exposure dose adjustment inoculations is inoculated in (2ml/ hole) in the 6 porocyte culture plates 37 ℃, 5%CO
2Cultivate in the incubator of saturated humidity 24h adherent after, dosing (cryptotanshinone 4.0 μ g/ml).Change no medicine culture medium behind the irradiation 4h, put and continue to cultivate 8-10d in the incubator, the Giemsa dyeing of the fixing back of methanol, counting is respectively organized clone's number of cell number 〉=50 cell.Calculating colony-forming efficiency (PE) and cell survival fraction (surviving fraction, SF).Each dose point is established 3 parallel sampless, gets mean.
Colony-forming efficiency (PE)=colony number/inoculating cell number * 100%;
Cells survival mark (SF)=each exposure dose PE/ does not shine PE * 100%.
Use many targets and click model SF=1-(1-e-D/D0) N match cell survival curve, calculate and respectively to organize the radiosensitivity parameter: whole slope D0 value, Dq Dq value, extrapolated value N and radiation sensitization than (sensitization enhancement ratio, SER).
Radiation sensitization is than the SF2 value of the SF2 value/irradiation dosing of (SER)=simple irradiation.
6. statistical procedures:
Adopt SPSS13.0 software to carry out statistical analysis.Every part of specimen parallel assay 6 holes in the mtt assay, repeated trials 3 times.With
One-way ANOVA check is relatively adopted in expression between group.
Experimental result:
1. cryptotanshinone is to the inhibitory action of Hela cell proliferation:
Mtt assay detects, and the cryptotanshinone of variable concentrations (0.5,1,2,4,8,10,16 μ g/ml) is respectively behind administration 24h, 48h and the 72h, and the growth of Hela cell is obvious inhibitory action.The IC50 value of drug effect 24h, 48h and 72h is respectively: 17.8 μ g/ml, 8.17 μ g/ml, 6.55 μ g/ml, the IC20 value is respectively: 4.0 μ g/ml, 1.17 μ g/ml, 0.96 μ g/ml.The result shows: cell inhibitory rate is relevant with drug level and action time, multifactor analysis of variance result shows that cell inhibitory rate has remarkable significant difference (P＜0.01) between different pharmaceutical concentration processed group, and remarkable significant difference (P＜0.05) is also arranged between processed group different action times.(seeing Table 1)
Table 1: the cryptotanshinone of variable concentrations to the growth inhibited effect of Hela cell (
N=6)
Annotate: compare with matched group
*P＜0.05,
*P＜0.01
2. cryptotanshinone is to the radiosensitizing effect of Hela cell:
The clone forms analytical applications in the research of cryptotanshinone to cervical cancer tumer line Hela radiosensitizing effect, establishes simple irradiation group and administration irradiation group, and the administration group is: cryptotanshinone 4.0 μ g/ml (the drug level IC20 that suppresses cell proliferation 20%).Carry out the various dose roentgenization after hatching Hela cell 24h after the administration, counting 8-12d rear clone formation rate is calculated and is respectively organized cell survival fraction, draws the cell survival curve (see figure 1).The Sigmaplot10.0 computed in software goes out its D0 value, Dq value, N value (seeing Table 2).Radiation sensitization ratio=SF2 (matched group)/SF2 (irradiation dosing group)=0.49/0.35=1.4.Compare with simple irradiation group, the radiation sensitization ratio of cryptotanshinone (IC20) is: 1.4, illustrate that cryptotanshinone has increased the radiosensitivity of Hela cell.
Table 2 is respectively organized the radiation biological mathematic(al) parameter
| Group | ??D 0 | ??D q | ??N | ??SF 2 |
| Matched group | ??2.639 | ??0.458 | ??1.088 | ??0.49 |
| Irradiation+cryptotanshinone group | ??1.959 | ??0.257 | ??0.978 | ??0.35 |
3. conclusion: cryptotanshinone has cytotoxicity and radiosensitizing effect preferably to cervical cancer tumer line Hela.
Cryptotanshinone is to the radiosensitizing effect of lotus H22 liver cancer mouse
1 materials and methods
1.1 material
(1) animal and tumor strain: 48 of healthy Kunming mouses, male and female half and half, body weight 18～22g is provided by Institute of Radiation Medicine, Chinese Academy of Medical Sciences's Experimental Animal Center.Mice H22 hepatoma carcinoma cell is provided by institute of radio-medicine's Experimental Animal Center.
(2) medicine: cryptotanshinone is provided by Chinese medicine and biological products assay institute, tween 80 (25%) dissolving, ultrasonic 30min; CMNa is that Shandong Luye Pharmaceutical Co., Ltd. produces (lot number 200811162), is made into 1.0mmol/kg with normal saline, matching while using.
1.2 experimental technique
1.2.1 tumor inoculation: aseptic condition extracts the H22 liver cancer mouse ascites that 6-8d goes down to posterity and inoculates down, with normal saline diluting cells suspension.Count tumor cell with cell counting count board, cell concentration is adjusted into 1.0 * 107/ml, every mice bottom right sole subcutaneous vaccination 0.2ml.
1.2.2 animal grouping and medication:
A week behind the animal inoculation is according to the evenly grouping of size of tumor growth.Be divided into 5 groups: concentration group (10mg/kg), cryptotanshinone low concentration group (5mg/kg) in blank group, simple irradiation group, positive controls (CMNa), cryptotanshinone high concentration group (20mg/kg), the cryptotanshinone, every group 8, male and female half and half and sub-cage rearing.Blank group: intraperitoneal injection of saline 0.3ml/ only; Positive controls: lumbar injection 1.0mmol/kg CMNa normal saline solution 0.3ml/ only; Cryptotanshinone administration group: tween 80 with 25% and physiological saline solution, ultrasonic 30min, the preparation high dose group (20mg/kg), after be diluted to middle dosage (10mg/kg) and low dosage (5mg/kg) successively.Positive controls and administration group (high, medium and low) are respectively pre-irradiation 30min lumbar injection (0.3ml/ only).The length of tumor pawl was measured in the irradiation back every one day, calculate the relative volume of tumor.
1.3 reagent and instrument:
Tween 80: available from Beijing ancient cooking vessel state biotechnology Co., Ltd (Genview packing); Irradiation apparatus: Canadian Gamma II 40 is provided by the institute of radio-medicine, is irradiation source with 137Cs, exposure dose rate 0.78Gy/min; Slide gauge: Shanghai measuring device tool factory.
1.4 illuminating method:
Each 4 mices, waking state is irradiation down.During irradiation mice is fixed, the rear solid end of inoculated tumour is exposed in the irradiation field, non-irradiated site covers with stereotype.Exposure dose is 5Gy.
1.5 observation index:
Irradiation back mice with tumor ordinary circumstance is as feed, activity; Every other day measure the length of tumor pawl, calculate gross tumor volume; Shine and put to death mice in back 22 days, strip tumor and weigh.Calculate tumour inhibiting rate, tumor growth slack time, enhanced sensitivity coefficient (EF).
The tumor growth delay time (TGD): it is 3 times of doubling times of tumor (TGT3) that gross tumor volume grows to the preceding 3 times of required times of radiotherapy, and the difference of the TGT3 of matched group (or experimental group) various dose subgroup and the TGT3 of blank group is TGD.Enhanced sensitivity coefficient (EF)=administration irradiation group TGD/ irradiation group merely TGD, EF＞1 prompting has radiosensitizing effect.
1.6 statistical procedures:
Adopt SPSS13.0 software to carry out statistical analysis.Each organize numerical value with
One-way ANOVA check is relatively adopted in expression between group.
2 results
2.1 the cryptotanshinone of various dose is to the radiosensitizing effect of lotus H22 liver cancer mouse
3 doubling times of gross tumor volume and tumor growth delay time see Table 3.
The time delay of table 3 lotus H22 liver cancer mouse tumor growth (
N=8)
| Group | The growth natural law | The average retardation natural law | ??EF |
| Blank group | ??3.9±0.583 | ||
| Single irradiation group | ??7.5±0.843 | ??3.6 | |
| The CMNa matched group | ??10.3±0.672 | ??6.4 | ??1.78 |
| Administration irradiation (low dosage) | ??10.8±0.953 | ??6.9 | ??1.91 |
| Administration irradiation (middle dosage) | ??10.6±0.654 | ??6.7 | ??1.86 |
| Administration irradiation (high dose) | ??8.3±0.615 | ??4.4 | ??1.22 |
The result shows: cryptotanshinone has radiosensitizing effect preferably to lotus H22 liver cancer mouse.
Embodiment 3
Cryptotanshinone is to the radiosensitizing effect of lotus EMT6 breast carcinoma mice
Experimental technique is with embodiment 2, and experimental result sees Table 4:
The time delay of table 4 lotus EMT6 breast carcinoma mouse tumor growth (
N=8)
| Group | The growth natural law | The average retardation natural law | ??EF |
| Blank group | ??10.1±0.423 |
| Group | The growth natural law | The average retardation natural law | ??EF |
| Single irradiation group | ??14.7±0.329 | ??4.6 | |
| The CMNa matched group | ??17.2±0.642 | ??7.1 | ??1.54 |
| Administration irradiation (low dosage) | ??18.3±0.587 | ??8.2 | ??1.78 |
| Administration irradiation (middle dosage) | ??17.6±0.378 | ??7.5 | ??1.63 |
| Administration irradiation (high dose) | ??15.3±0.571 | ??5.2 | ??1.12 |
The result shows: cryptotanshinone has radiosensitizing effect preferably to lotus EMT6 breast carcinoma mice.
Cryptotanshinone is to the radiosensitizing effect of lotus Lewis lung cancer mice
Experimental technique is with embodiment 2, and experimental result sees Table 5:
The time delay of table 5 lotus Lewis lung cancer mouse tumor growth (
N=8)
| Group | The growth natural law | The average retardation natural law | ??EF |
| Blank group | ??5.9±0.723 | ||
| Single irradiation group | ??11.6±0.462 | ??5.7 | |
| The CMNa matched group | ??13.6±0.795 | ??7.7 | ??1.35 |
| Administration irradiation (low dosage) | ??14.9±0.386 | ??9.1 | ??1.58 |
| Administration irradiation (middle dosage) | ??14.1±0.247 | ??8.2 | ??1.43 |
| Administration irradiation (high dose) | ??12.1±0.835 | ??6.2 | ??1.09 |
The result shows: cryptotanshinone has radiosensitizing effect preferably to lotus Lewis lung cancer mice.
Embodiment 5 (1000)
Cryptotanshinone 100g adds lactose 397g, starch,pregelatinized 93g, and hydroxypropyl cellulose 15g, cross-linking sodium carboxymethyl cellulose 29.8g, magnesium stearate 7.5g, mix homogeneously, pure water is granulated, dry tabletting, bag film-coat.
Cryptotanshinone 100g adds dextrin 100g, and lactose 270g uses 70% alcohol granulation, and drying is encapsulated, makes 1000 seed lac wafers.
Embodiment 7 (1000)
Cryptotanshinone 40g adds in the fused Macrogol 4000 of 100g, stirs and makes whole dissolvings and mix homogeneously, keeps splashing in the liquid paraffin (5～10 ℃) under 60 ℃ of constant temperatures, is condensed into drop pill, exhausts liquid paraffin, the choosing grain, promptly.
Embodiment 8
Cryptotanshinone 80g adds 2M NaOH and regulates pH8.0, adds the injection water to 2000ml, 0.22 μ m microporous filter membrane microfiltration, and packing (every bottle of 5ml), sterilization promptly gets the cryptotanshinone injection.
Embodiment 9
Cryptotanshinone 40g adds 2M NaOH and regulates pH8.0, adds glycine 200g, adds the injection water to 1000ml, 0.22 μ m microporous filter membrane microfiltration, and packing under the aseptic condition (every bottle of 2ml), lyophilization, gland promptly gets the freeze-dried powder that contains cryptotanshinone.
After the preferred embodiment that describes in detail, being familiar with this technology personage can be well understood to, can carry out various variations and modification not breaking away under above-mentioned claim and the spirit, all foundations technical spirit of the present invention all belongs to the scope of technical solution of the present invention to any simple modification, equivalent variations and modification that above embodiment did.And the present invention also is not subjected to the restriction of the embodiment that gives an actual example in the description.
Claims (6)
- Cryptotanshinone in preparation medicine for treating tumor thing as the application aspect the radio sensitization agent.
- 2. application as claimed in claim 1 is characterized in that cryptotanshinone application as the radio sensitization agent in preparation treatment cervical cancer medicine.
- 3. application as claimed in claim 1 is characterized in that cryptotanshinone application as the radio sensitization agent in preparation treatment liver-cancer medicine.
- 4. application as claimed in claim 1 is characterized in that cryptotanshinone application as the radio sensitization agent in preparation treatment breast cancer medicines.
- 5. application as claimed in claim 1 is characterized in that cryptotanshinone application as the radio sensitization agent in preparation treatment lung-cancer medicament.
- 6. each described application of claim 1-5 is characterized in that and will make sheet, capsule or injection after cryptotanshinone and one or more pharmaceutically acceptable carriers, excipient or the mixing diluents.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910068497A CN101862339A (en) | 2009-04-17 | 2009-04-17 | Use of cryptotanshinone as radiation sensitizing medicament in oncotherapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910068497A CN101862339A (en) | 2009-04-17 | 2009-04-17 | Use of cryptotanshinone as radiation sensitizing medicament in oncotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101862339A true CN101862339A (en) | 2010-10-20 |
Family
ID=42954399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910068497A Pending CN101862339A (en) | 2009-04-17 | 2009-04-17 | Use of cryptotanshinone as radiation sensitizing medicament in oncotherapy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101862339A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389559A (en) * | 2011-11-21 | 2012-03-28 | 许从玉 | Traditional Chinese medicine composition and application as radiotherapy sensitizer |
| CN105963637A (en) * | 2016-06-15 | 2016-09-28 | 中山大学 | Application of combination of cryptotanshinone and curcumin in preparation of drug for treating tumor |
| CN115814080A (en) * | 2022-12-12 | 2023-03-21 | 安徽科技学院 | Photodynamic therapeutic agent containing cryptotanshinone and application thereof |
-
2009
- 2009-04-17 CN CN200910068497A patent/CN101862339A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389559A (en) * | 2011-11-21 | 2012-03-28 | 许从玉 | Traditional Chinese medicine composition and application as radiotherapy sensitizer |
| CN105963637A (en) * | 2016-06-15 | 2016-09-28 | 中山大学 | Application of combination of cryptotanshinone and curcumin in preparation of drug for treating tumor |
| CN105963637B (en) * | 2016-06-15 | 2020-01-14 | 中山大学 | Application of cryptotanshinone and curcumin in preparation of tumor treatment medicine |
| CN115814080A (en) * | 2022-12-12 | 2023-03-21 | 安徽科技学院 | Photodynamic therapeutic agent containing cryptotanshinone and application thereof |
| CN115814080B (en) * | 2022-12-12 | 2023-07-07 | 安徽科技学院 | Photodynamic therapeutic agent containing cryptotanshinone and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101007050B (en) | Extract of an traditional Chinese medicine containing isopsoralen, preparation method and use thereof | |
| CN105963637A (en) | Application of combination of cryptotanshinone and curcumin in preparation of drug for treating tumor | |
| CN103948689A (en) | Medicinal composition for treating non-small cell lung cancer and application thereof | |
| CN101862339A (en) | Use of cryptotanshinone as radiation sensitizing medicament in oncotherapy | |
| CN102389559B (en) | Traditional Chinese medicine composition and application as radiotherapy sensitizer | |
| CN103263433A (en) | Medical application of natural product 6-shogaol in enhancing chemosensitivity of pancreatic cancer on gemcitabine and compound drug composite of natural product 6-shogaol | |
| CN101229175A (en) | Medical applications of couple protopanoxadiol derivatives and compound body thereof | |
| CN102178842A (en) | Pharmaceutical composition for treating tuberculosis and application thereof | |
| CN1995020B (en) | Radioactive iodine-17- allylamino-17-demethoxygeldanamycin and its preparation method | |
| CN101143148A (en) | Application of paris saponin I and its derivatives | |
| CN100406026C (en) | Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method | |
| CN101904849A (en) | Application of sanguinarine for preparing tumour radiotherapy sensitized medicine | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN1321127C (en) | Iodine (I)-23-hydroxyl betulinic acid, rpeparation method and application thereof | |
| CN101229158B (en) | Medicine compounds for treating tumour and applications thereof | |
| CN101549032B (en) | Drug composition with the effect of anti-lung cancer and application in preparing anti-lung cancer drug | |
| CN101422534A (en) | Radio therapy sensitization composite preparation | |
| CN100381129C (en) | Antitumor animal medicine and its preparing method | |
| CN102440994A (en) | Application of ganoderic acid G as immune synergist and super-antigen dependent therapeutic medicine in tumour treatments | |
| CN107362158A (en) | Purposes of the Strychnos nux-vomica aglycon in antineoplastic is prepared | |
| CN101199534A (en) | Anti-tumor function of raw panoxadiol derivative | |
| CN107184912A (en) | The positive disperse accumulations compound preparation of one breeding and its application | |
| CN104800193A (en) | Pharmaceutical use of guaiol | |
| RU2463053C1 (en) | Pharmaceutical composition for oncological diseases | |
| Chang et al. | Experimental study on growth inhibition against anaplastic thyroid carcinoma of animal model by application of ginsenoside Rg1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20101020 |